Geode Capital Management
BRNS

Geode Capital Management’s Barinthus Biotherapeutics BRNS Stock Holding History

Geode Capital Management’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,568
Closed -$6.62K – 4463
2026
Q1 		$6.62K Hold
11,568
– – ﹤0.01% 4497
2025
Q4 		$8.1K Hold
11,568
– – ﹤0.01% 4441
2025
Q3 		$14.5K Hold
11,568
– – ﹤0.01% 4436
2025
Q2 		$10.5K Hold
11,568
– – ﹤0.01% 4416
2025
Q1 		$11.5K Hold
11,568
– – ﹤0.01% 4426
2024
Q4 		$13.9K Hold
11,568
– – ﹤0.01% 4417
2024
Q3 		$14.2K Hold
11,568
– – ﹤0.01% 4435
2024
Q2 		$16.2K Hold
11,568
– – ﹤0.01% 4485
2024
Q1 		$27.8K Hold
11,568
– – ﹤0.01% 4432
2023
Q4 		$41.2K Buy
+11,568
New +$39.1K ﹤0.01% 4397

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Geode Capital Management's BRNS Position: Q2 2026 in Review

Geode Capital Management sold out of Barinthus Biotherapeutics (BRNS) in Q2 2026, closing a stake of 11,568 shares — an estimated $6.62K sold.

Geode Capital Management first reported a position in BRNS in Q4 2023 and held it in 10 quarters. The position peaked at $41.2K in Q4 2023. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

  • Geode Capital Management reported no remaining Barinthus Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Geode Capital Management sold 11,568 Barinthus Biotherapeutics shares in Q2 2026, an estimated $6.62K.
  • Geode Capital Management first reported a position in Barinthus Biotherapeutics in Q4 2023 and held it in 10 quarters.
  • Geode Capital Management's Barinthus Biotherapeutics position peaked at $41.2K in Q4 2023.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.